Impact of Neutrophil Extracellular Traps on Tissue Plasminogen Activator Induced Thrombolysis in Acute Ischemic Stroke Patients (THROMBONETS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02907736|
Recruitment Status : Withdrawn (replaced by a new study)
First Posted : September 20, 2016
Last Update Posted : March 19, 2018
Acute Ischemic stroke (AIS) remains a leading cause of adult disability, cognitive impairment and mortality worldwide despite the development of revascularization therapies (intravenous Tissue Plasminogen Activator (t-PA) and endovascular therapy). Thrombosis resistance after IV t-PA therapy is frequent especially in case of AIS with proximal occlusion. In recent years, neutrophil extracellular traps (NETs) have been identified as major triggers and structural factors of various forms of thrombosis. NETs are extracellular webs primarily composed of DNA from neutrophils. A recent study shows that the NETs burden in coronary thrombi is positively correlated with the infarct size and negatively correlated with electrocardiogram (ST-segment) resolution. This later study revealed that in vitro addition of DNase I accelerated the t-PA-induced thrombolysis of coronary thrombi. NETs could, in consequence, be promising targets for improved thrombolysis in AIS.
The aim of this study is to assess the impact of NETs composition of thrombi retrieved during endovascular therapy in AIS patients on IV t-PA induced thrombolysis, clinical outcome and AIS etiologies.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Actual Study Start Date :||November 12, 2015|
|Actual Primary Completion Date :||July 1, 2017|
|Actual Study Completion Date :||July 1, 2017|
- thrombus origin [ Time Frame: baseline ]according to the etiology of the stroke (TOAST classification)
- red cells counts [ Time Frame: baseline ]quantitative assessment of the relative fractions of the main constituents after Hematoxylin and Eosin staining :
- white cells counts [ Time Frame: baseline ]quantitative assessment of the relative fractions of the main constituents after Hematoxylin and Eosin staining
- platlet counts [ Time Frame: baseline ]quantitative assessment of the relative fractions of the main constituents after Hematoxylin and Eosin staining
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02907736
|Fondation Ophtalmologique Adolphe de Rothschild|
|Paris, France, 75019|
|Principal Investigator:||Jean-Philippe Désilles, MD||Fondation OPH A. de Rothschild|
|Study Chair:||Mikael Mazighi, MD, PhD||Fondation OPH A. de Rothschild|